|
|
Article: The FDA has granted priority review status to Gilead Science's hypertension drug ambrisentan on a priority basis.(PRODUCT NEWS)
- Article from:
- Medical Marketing & Media
- Article date:
- April 1, 2007
CopyrightCOPYRIGHT 2007 Haymarket Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The FDA has granted priority review status to Gilead Science's hypertension drug ambrisentan on a priority basis. Ambrisentan is a potential treatment for pulmonary arterial hypertension, a ...
Related newspaper, magazine, and journal articles:
|
|
Article: Govt strengthening Education Sector on priority ...
PPI - Pakistan Press International;
September 23, 2007 ;
700+ words
... ... that government is strengthening the Education Sector on priority basis. He said that huge resources are being spent on the promotion ... declared as dangerous, therefore, its rehabilitation on priority basis is very essential. Ch. Pervaiz Elahi further said that ...
|
|